Table 3

Summary of outcomes evaluated in single studies

OutcomeStudyEffect size (95% CI)
Urea (24 hours)Wolak et al16MD=2.17 (−5.22 to 9.56)
Diastolic blood pressure (48 hours)Wolak et al16MD=0.30 (−5.01 to 5.61)
Systolic blood pressure (48 hours)Wolak et al16MD=−2.10 (−12.98 to 8.78)
Hypertensive treatmentWolak et al16RR=0.17 (0.01 to 3.69)
DeathBainey et al18RR=3.15 (0.13 to 78.17)
Myocardial infarctionBainey et al18No events
StrokeBainey et al18RR=3.15 (0.13 to 78.17)
Congestive heart failureBainey et al18No events
RehospitalisationBainey et al18RR=7.49 (0.38 to 146.89)
Interleukin 18 (IL 18) (≥120 ng/mL)Coca et al190.89 (0.65 to 1.23)*
Kidney injury molecule 1 (KIM 1) (≥1.15 ng/mL)Coca et al191.09 (0.82 to 1.44)*
Liver fatty acid binding protein (L-FABP) (≥170 ng/mL)Coca et al190.97 (0.73 to 1.3)*
Neutrophilgelatinase-associated lipocalin (NGAL) (≥120 ng/mL)Coca et al190.84 (0.60 to 1.16)*
  • *Adjusted for sex, age, white, CKD-EPI eGFR, diabetes, hypertension, congestive heart failure, myocardial infarction, cardiac cauterisation in past 48 hours, electic surgery and type of surgery (CABG, valve, both).

  • MD, mean difference; RR, relative risk.